Psychiatr. praxi. 2016;17(2):48-52 | DOI: 10.36290/psy.2016.013

Some issues of antidepressant efficacy and tolerability relevant for routine clinical practice

prof. MUDr. Eva Češková, CSc.
1 CEITEC-MU
2 Psychiatrická klinika FN Brno
3 KIO LF Univerzity Ostrava
4 Oddělení psychiatrie, FN Ostrava

Current possibilities of available antidepressants (AD) are limited. In spite of great heterogeneity of depressive disorders, monoamines remain the main target of psychopharmacotherapy. The differences in treatment response are associated with genetic variability. The developing field of pharmacogenetics strives for individualized treatment; however, in routine clinical practice the choice of antidepressant is based on individual efficacy, tolerability and alignment of symptoms to a biochemical alteration. The presence of an adequate quantity of the active substance in CNS targets is undoubtedly a precondition for efficacy. This raises the issue of adherence. The most frequent reasons for non-adherence are insufficient efficacy, including residual symptoms, as well as side effects, particularly sexual dysfunction, and weight gain. Attitudes to treatment may also play a significant role.

Keywords: antidepressants, side effects, adherence, attitudes to treatment

Published: June 10, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Some issues of antidepressant efficacy and tolerability relevant for routine clinical practice. Psychiatr. praxi. 2016;17(2):48-52. doi: 10.36290/psy.2016.013.
Download citation

References

  1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917. Go to original source... Go to PubMed...
  2. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25: 2289-2304. Go to original source... Go to PubMed...
  3. Zohar J, Stahl S, Möller HJ, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 2015; 25: 2318-2325. Go to original source... Go to PubMed...
  4. Nestler EJ. Epigenetic mechanisms of depression. JAMA Psychiatry 2014; 71: 454-456. Go to original source... Go to PubMed...
  5. Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012; 16: 61-71. Go to original source... Go to PubMed...
  6. Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015; 11: 875-888. Go to original source...
  7. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14: 536-546. Go to original source... Go to PubMed...
  8. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci 2012; 9: 41-46.
  9. Šilhán P, Uřinovská R, Hýža M. Monitoring sérových hladin antidepresiv v klinické praxi - pro a proti. Psychiatrie 2013; 17 (Suppl. 1): s 35.
  10. Romera I, Pérez V, Ciudad A, et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry 2013; 13: 51-58. Go to original source... Go to PubMed...
  11. Conradi HJ, Ormel J, de Jonge P. Symptom profiles of DSM-IV-defined remission, recovery, relapse, and recurrence of depression: the role of the core symptoms. Depress Anxiety 2012; 29: 638-645. Go to original source... Go to PubMed...
  12. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat 2012; 2012: ID 630206. Go to original source... Go to PubMed...
  13. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord 2011; 134: 20-31. Go to original source... Go to PubMed...
  14. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014; 44: 2029-2040. Go to original source... Go to PubMed...
  15. El Hammi E, Samp J, Rémuzat C, et al. Difference of perceptions and evaluation of cognitive dysfunction in major depressive disorder patients across psychiatrists internationally. Ther Adv Psychopharmacol 2014; 4: 22-29. Go to original source... Go to PubMed...
  16. Papakostas GI, Culpepper L. Understanding and managing cognition in the depressed patient. J Clin Psychiatry 2015; 76: 418-425. Go to original source... Go to PubMed...
  17. Mohr P, Bravermanová A, Kratochvílová Z, Melicher T, Knytl P. Kognitivní poruchy u deprese. Čes. a slov. Psychiatrie 2015; 111: 283-289.
  18. Keshavan MS, Vinogradov S, Rumsey J, Sherrill J, Wagner A. Cognitive training in mental disorders: update and future directions. Am J Psychiatry 2014; 171: 510-522. Go to original source... Go to PubMed...
  19. Navrátilová P, Češková E, Přikryl R, Kučerová H. Profil a dynamika kognitivního výkonu při léčbě antidepresivy (pilotní studie). Čes a slov Psychiatrie 2007; 103: 168-174. Go to original source...
  20. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145: 43-57. Go to original source... Go to PubMed...
  21. Solé B, Jiménez E, Martinez-Aran A, Vieta E. Cognition as a target in major depression: new developments. Eur Neuropsychopharmacol 2015; 25: 231-247. Go to original source... Go to PubMed...
  22. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicentre study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 (Suppl 3): 10-21.
  23. Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015; 28: 418-423. Go to original source... Go to PubMed...
  24. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry 2007; 62: 321-326. Go to original source... Go to PubMed...
  25. Toups MS, Myers AK, Wisniewski SR, et al. Relationship between obesity and depression: characterstics and treatment outcomes with andepressant medication. Psychosom Med 2013; 75: 863-872. Go to original source... Go to PubMed...
  26. Češková E. Deprese, antidepresivní léčba a přírůstek hmotnosti. Psychiatrie 2009; 13(Suppl. 2): 46-47.
  27. Correll CU, Detraux J, De Lepeleire J, deHert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119-136. Go to original source... Go to PubMed...
  28. Kloiber S, Domschke K, Ising M, et al. Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry 2015; 76: e802-808. Go to original source... Go to PubMed...
  29. Holma IA, Holma KM, Melartin TK, Isometsä ET. Treatment attitudes and adherence of psychiatric patients with major depressive disorder: a five-year prospective study. J Affect Disord 2010; 127: 102-112. Go to original source... Go to PubMed...
  30. Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15: 34-44. Go to original source... Go to PubMed...
  31. Jacob SA, Ab Rahman AF, Hasalli MAA. Attitudes and beliefs of patients with chronic depression toward antidepressants and depression. Neuropsychiatr Dis Treat 2015; 11: 1339-1347. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.